The important partnership with the industry association marks a milestone in Arvato Systems' market positioning and opens up new opportunities to once again expand its expertise in the pharmaceutical industry. Stefan Moch, Vice President Health at Arvato Systems, emphasizes: "We are extremely pleased to join the BAH and become part of this important network. As a provider of IT solutions for the pharmaceutical industry, we see this as an ideal opportunity to further strengthen our expertise in the digital transformation of pharmaceutical manufacturers and to address the challenges of the industry with our services."
As a member of the association, Arvato Systems can benefit from numerous advantages. The BAH offers a unique platform for exchanging ideas with the most important players in the pharmaceutical industry. These include pharmaceutical manufacturers, suppliers, market and opinion research institutes in the healthcare sector, as well as pharmacists, lawyers, publishers and agencies. By working with this network, the IT specialist can deepen its understanding of the challenges and needs of the industry and target its solutions accordingly.
Arvato Systems has already proven itself as a reliable IT service provider in the pharmaceutical environment in the past. With solutions such as Arvato CSDB for the serialization of pharmaceuticals, the platbricks® Healthcare Suite and the operation of national verification systems in 17 EU countries, Arvato Systems has been able to win over a large number of customers. By joining the BAH, the company is looking forward to further impetus from the pharmaceutical sector to accompany the industry on its digitalization path in the long term.
About BAH
The German Association of Pharmaceutical Manufacturers (BAH) is the pharmaceutical industry's largest association of the pharmaceutical industry in Germany. It represents the interests of around 400 member companies, which employ approximately 80,000 people in Germany. The companies organized in the BAH make a significant contribution to securing the supply of medicines in Germany. For example, they provide almost 80 percent of the over-the-counter medicines sold in pharmacies and almost two-thirds of the prescription medicines, as well as a large proportion of the substance-based medical products for patients. More information about the BAH is available at https://www.bah-bonn.de/en